Status:
COMPLETED
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
Lead Sponsor:
Endo Pharmaceuticals
Conditions:
Chronic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.
Detailed Description
Patients with low back pain who are sub-optimally responsive to their current analgesic treatment begin open-label treatment with oxymorphone extended release (ER). During the Open-Label Titration Per...
Eligibility Criteria
Inclusion
- Males or females 18 years of age or older
- opioid naïve
- Have an initial pain intensity score of at least 50 mm VAS
- In good health as determined by the investigator on the basis of medical history and physical examination
- Have moderate to severe chronic non-neuropathic LBP that has been present daily for at least several hours per day for a minimum of three months prior to the Screening
- Any adjunct therapy for back pain such as physical therapy, biofeedback therapy, acupuncture therapy or herbal remedies, based on the patient's current status should remain unchanged during the period of participation of the patient
- Written informed consent
Exclusion
- Pregnant and/or lactating
- Radiculopathy, fibromyalgia, reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, severe lower extremity weakness or numbness, bowel or bladder dysfunction secondary to cauda equina compression, diabetic amyotrophy, meningitis, discitis, or back pain due to secondary infection or tumor
- Cannot or will not agree to stop local regional pain treatments during the study (nerve/plexus blocks or ablation, neurosurgical procedures for pain control, or inhalation analgesia). The patient must not have a nerve/plexus block within 4 weeks of screening
- Intend to alter physical therapy regimen during the study.
- Surgical procedures directed towards the source of back pain within 6 months of screening
- Pain which is secondary to confirmed or suspected neoplasm
- Dysphagia or difficulty swallowing tablets or capsules, or an inability to take oral medication
- Significant prior history of substance abuse or alcohol abuse
- Use of any investigational medication within 30 days prior to the first dose of study medication
- Previous exposure to oxymorphone
- History of clinically significant intolerance to oxymorphone or a known hypersensitivity to opioid analgesics
- History of seizure
- Ileostomy or colostomy
- Use of MAO inhibitor within 14 days prior to the start of study medication
- Other clinically significant conditions as judged by the investigator
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00225797
Start Date
November 1 2004
End Date
July 1 2005
Last Update
January 2 2024
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern Drug Research
Hueytown, Alabama, United States, 35023
2
Phoenix Center for Clinical Research
Phoenix, Arizona, United States, 85015
3
Express Care Clinical Research
Colorado Springs, Colorado, United States, 80909
4
New England Research
Bridgeport, Connecticut, United States, 06606